Thursday, July 10, 2025
spot_img

Bharat Biotech again applies for vaccine’s emergency approval

Date:

Share post:

spot_imgspot_img

New Delhi, Dec 23: Hyderabad-based Bharat Biotech, which is developing the country’s indigenous coronavirus vaccine in collaboration with the Indian Council of Medical Research, on Wednesday again applied to the Drug Controller General of India for the emergency use authorisation.
“The company applied for the emergency use authorisation in the evening,” a company source told IANS.
Emergency Use Authorisation is a mechanism to facilitate the availability and use of medical countermeasures, including vaccines, during public health emergencies.
Bharat Biotech had first applied for the emergency use authorisation of its vaccine on December 7 and presented its proposal, along with the interim safety and immunogenicity data of Phase 1 and 2 clinical trials.
The Central Drugs Standard Control Organisation’s (CDSCO) expert panel had, however, recommended that the firm should present the safety and efficacy data from the ongoing Phase 3 clinical trial in the country for further consideration.
Bharat Biotech’s COVAXIN, an inactivated vaccine candidate, is currently undergoing Phase 3human clinical trials on 26,000 volunteers over 25 centres across India, after having undergone Phase 1 and 2 trials involving 1,000 volunteers.
Meanwhile, the Serum Institute of India (SII) has also submitted the additional data asked by the DCGI determining safety and immunogenicity of its COVID-19 vaccine candidate, Covishield.
America’s Pfizer was the first to apply on December 4, followed by Pune-based SII and Bharat Biotech who applied on December 6 and 7, respectively. Pfizer had, however, requested more time to make presentation before the committee.
Pfizer, whose vaccine has been authorized in the US, the UK and Canada, has written to DCGI seeking a fresh date to present its case for the EUA of their vaccine candidate BNT162b2, after it failed to present its data before the vaccine reviewing committee of the CDSCO earlier.
India is likely to have a Covid-19 vaccine approved for emergency use before December end as CDSCO’s expert panel is set to review the application of SII, Bharat Biotech and Pfizer for emergency use authorisation. (IANS)

spot_imgspot_img

Related articles

With 15 days to go, 66 pc of Bihar voters already covered under rolls revision: ECI

New Delhi, July 10: As many as 5.22 crore enumeration forms, accounting for 66.16 per cent of the...

Kapil Sharma’s newly opened cafe attacked by Khalistani terrorist

Mumbai, July 10: Comedian turned actor Kapil Sharma’s newly launched Kap's Cafe in Surrey, British Columbia was targeted...

Manipur Guv highlights state’s sports legacy, stresses youth engagement in Durand Cup

Imphal, July 10: Manipur Governor Ajay Kumar Bhalla on Thursday highlighted the state’s legacy as a powerhouse of...

Wimbledon 2025: Amanda Anisimova stuns world No. 1 Sabalenka to reach maiden final

London, July 10: Amanda Anisimova of the United States produced the performance of her career, toppling top seed...